"Diphtheria Toxin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ADP-ribosylating polypeptide produced by CORYNEBACTERIUM DIPHTHERIAE that causes the signs and symptoms of DIPHTHERIA. It can be broken into two unequal domains: the smaller, catalytic A domain is the lethal moiety and contains MONO(ADP-RIBOSE) TRANSFERASES which transfers ADP RIBOSE to PEPTIDE ELONGATION FACTOR 2 thereby inhibiting protein synthesis; and the larger B domain that is needed for entry into cells.
- Diphtheria Toxin
- Toxin, Corynebacterium Diphtheriae
- Corynebacterium Diphtheriae Toxin
Below are MeSH descriptors whose meaning is more general than "Diphtheria Toxin".
Below are MeSH descriptors whose meaning is more specific than "Diphtheria Toxin".
This graph shows the total number of publications written about "Diphtheria Toxin" by people in this website by year, and whether "Diphtheria Toxin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Diphtheria Toxin" by people in Profiles.
IL-33-mediated Eosinophilia Protects against Acute Lung Injury. Am J Respir Cell Mol Biol. 2021 05; 64(5):569-578.
DNA nanodevices map enzymatic activity in organelles. Nat Nanotechnol. 2019 03; 14(3):252-259.
Diphtheria toxin-mediated ablation of lymphatic endothelial cells results in progressive lymphedema. JCI Insight. 2016 09 22; 1(15):e84095.
Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice. J Neurosci. 2014 Feb 19; 34(8):3090-4.
In mice lacking V2a interneurons, gait depends on speed of locomotion. J Neurosci. 2009 May 27; 29(21):7098-109.
In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity. 2002 Aug; 17(2):211-20.
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol. 1998 Jul; 39(1):63-73.
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998 Jan 15; 91(2):399-405.
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer. 1997 Jan; 33 Suppl 1:S34-6.
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.